Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01989598 · OUTCOME

Pharmacodynamic Markers of Trametinib

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma · Source last updated 2022-03-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Baseline, day 1 of course 2, progression

What was measured

Analyses will be descriptively summarized.

Analysis population: Data for this measure was not analyzed

Groups in this outcome

Treatment (Trametinib, Akt Inhibitor GSK2141795)

Patients receive trametinib orally PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease or who achieve less than PR after 4 courses may also receive Akt inhibitor GSK2141795 PO daily on days 1-28. Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Trametinib: Given PO Uprosertib: Given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Trametinib, Akt Inhibitor GSK2141795)0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
Analyses will be descriptively summarized.
groups
  1. description
    Patients receive trametinib orally PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease or who achieve less than PR after 4 courses may also receive Akt inhibitor GSK2141795 PO daily on days 1-28. Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Trametinib: Given PO Uprosertib: Given PO
    id
    OG000
    title
    Treatment (Trametinib, Akt Inhibitor GSK2141795)
population Description
Data for this measure was not analyzed
reporting Status
POSTED
time Frame
Baseline, day 1 of course 2, progression
title
Pharmacodynamic Markers of Trametinib
type
OTHER_PRE_SPECIFIED

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice